Thursday, February 3, 2011
[WATCH VIDEO]: Mayo Clinic Study Shows Crohns Disease Patients Benefit From Infliximab Plus Azathioprine
The use of infliximab (IFX) plus azathioprine (AZA) and infliximab monotherapy increase the likelihood of patients achieving long-term steroid-free clinical remission in patients with moderate to severe Crohns disease, according to a new study. This study represents the first time longer term outcome data has been available to show the advantages of the combination therapy and IFX monotherapy. Crohn's disease causes inflammation of the lining and wall of the large and/or small
